Physician profile
Kristine Landrian
NPI 1386224657
$458.64
in general payments reported to CMS, 2019-2025
14 companies · $459 in 2025
The $459 reported for 2025 was more than what 91% of Hospice and Palliative Medicine (Internal Medicine) providers received nationally (typical 2025 total: $77.77).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $458.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $68.29 | 2025 | Jakafi, Monjuvi, Zynyz |
| Janssen Biotech, INC. | $47.71 | 2025 | Darzalex, Tecvayli, Rybrevant |
| Merck Sharp & Dohme LLC | $45.66 | 2025 | Keytruda Qlex, Keytruda |
| Eisai INC. | $38.50 | 2025 | |
| Pharmaand Gmbh | $35.33 | 2025 | Rubraca |
| Tolmar, INC. | $33.04 | 2025 | Rubraca |
| Sobi, INC | $29.64 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $29.39 | 2025 | Onivyde |
| Aveo Pharmaceuticals, INC. | $28.00 | 2025 | |
| Daiichi Sankyo INC. | $24.09 | 2025 | Enhertu |
| Pharmacosmos Therapeutics INC. | $23.59 | 2025 | Monoferric |
| Astrazeneca Pharmaceuticals Lp | $19.96 | 2025 | Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $18.60 | 2025 | |
| Genzyme Corporation | $16.84 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristine Landrian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.